MBX

NASDAQ 已收盘

MBX Biosciences

53.41 USD
▼-0.01-0.02%
盘后 54.99 +2.96%
2026-11-19
市值
$2.46B
市盈率
—
EPS
-3.09
股息率
—
52 周区间
26.00 – 72.64
成交量
748.19K
Beta
0.18
目标价
95.09
52W 低 26.0052W 高 72.64
价格走势

公司简介

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo...